Atherosclerosis and Lipoproteins |
A) in the Promoter Region of Cholesteryl Ester Transfer Protein Gene in Japanese Hyperalphalipoproteinemic Subjects
From the Research Department, R&D Center, BML, Saitama (M.N., T.K., M.I., Y.S., H.H., T.E.); the Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka (S.Y., K.H., T.M., N.S.); and Nakajima Clinic, Akita (N.N.), Japan.
Correspondence to Shizuya Yamashita, MD, PhD, Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. E-mail shizu{at}imed2.med.osaka-u.ac.jp
AbstractCholesteryl
ester transfer protein (CETP) transfers cholesteryl ester (CE) from HDL
to apolipoprotein (apo) Bcontaining lipoproteins and plays a crucial
role in reverse cholesterol transport, which is a major
protective system against atherosclerosis. Genetic CETP
deficiency is the most common cause of a marked
hyperalphalipoproteinemia (HALP) in the Japanese, and various mutations
have been identified in the coding region as well as in the exon/intron
boundaries in the CETP gene. In the present study, we identified a
novel mutation in the promoter region of the CETP gene. This mutation
was a G-to-A substitution at the -69 nucleotide of the
promoter region (-69 G
A), corresponding to the second
nucleotide of the PEA3/ETS binding site
(CGGAA) located upstream of the
putative TATA box. Four (2.0%) of 196 unrelated subjects with a marked
HALP (HDL cholesterol
2.59 mmol/L=100 mg/dL) were
revealed to be heterozygous for the -69 G
A mutation, and the
allelic frequency of the mutant was 0.0102 in the subjects with a
marked HALP. The subjects with the -69 G
A mutation had low plasma
CETP levels. Reporter gene assay showed that this mutation markedly
reduced the transcriptional activities in HepG2 cells (8% of wild
type). These results suggested that this mutation would be dominant
negative. In conclusion, a novel -69 G
A mutation in the CETP gene
causes the decreased transcriptional activity leading to
HALP.
Key Words: cholesteryl ester transfer protein deficiency hyperalphalipoproteinemia mutation promoter PEA3/ETS binding site
This article has been cited by other articles:
![]() |
S. M. Boekholdt and J. F. Thompson Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J. Lipid Res., July 1, 2003; 44(6): 1080 - 1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Oka, S. Yamashita, T. Kujiraoka, M. Ito, M. Nagano, Y. Sagehashi, T. Egashira, M. N. Nanjee, K.-i. Hirano, N. E. Miller, et al. Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia J. Lipid Res., August 1, 2002; 43(8): 1236 - 1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nagano, S. Yamashita, K.-i. Hirano, M. Ito, T. Maruyama, M. Ishihara, Y. Sagehashi, T. Oka, T. Kujiraoka, H. Hattori, et al. Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader (R) assay J. Lipid Res., July 1, 2002; 43(7): 1011 - 1018. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |